Chengqing Wu
Chengqing Wu publishes mostly in Hematology, Pathology and Forensic Medicine and Genetics, on topics such as Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research and Multiple Myeloma Research and Treatments.
- World rank
- #4,319,047 of 7,710,434 ranked researchers
- Rank in United States
- #1,159,654 of 1,627,098
- Works
- 34
- Citations
- 608
- Citations per work
- 17.9
What does Chengqing Wu research?
Chengqing Wu's work is mostly in Medicine (68%), Biochemistry, Genetics and Molecular Biology (9%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences2367.7%
- Medicine2367.7%
- Everything else823.7%
- Life Sciences38.6%
- 1Hematology17% of their works
- 2Pathology and Forensic Medicine16% of their works
- 3Genetics16% of their works
- 4Oncology13% of their works
- 5Molecular Biology9% of their works
- 6Rheumatology5% of their works
Research topics
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Multiple Myeloma Research and Treatments
- Acute Myeloid Leukemia Research
- Protein Degradation and Inhibitors
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Colorectal Cancer Treatments and Studies
Which keywords describe Chengqing Wu's research?
The keywords of their largest research topics: Rituximab, Prognostic Factors, Classification, Lymphoma, Minimal Residual Disease, Chronic Lymphocytic Leukemia, Genomic Aberrations and Diagnosis Criteria.
- Cetuximab
- JAK2 Mutation
- Acute Lymphoblastic Leukemia
- BET Bromodomains
- AML
- Diagnosis Criteria
- Chronic Lymphocytic Leukemia
- Lymphoma
- Prognostic Factors
- Rituximab
- Classification
- Minimal Residual Disease
- Genomic Aberrations
- International Myeloma Working Group
- Acute Myeloid Leukemia
- PROTACs
- Childhood Cancer
- Myelofibrosis
- KRAS Mutations
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 19 words, with their numbers
- Rituximab242 topics
- Prognostic Factors203 topics
- Classification141 topic
- Lymphoma141 topic
- Minimal Residual Disease112 topics
- Chronic Lymphocytic Leukemia101 topic
- Genomic Aberrations101 topic
- Diagnosis Criteria71 topic
- International Myeloma Working Group71 topic
- AML61 topic
- Acute Myeloid Leukemia61 topic
- BET Bromodomains51 topic
- PROTACs51 topic
- Acute Lymphoblastic Leukemia41 topic
- Childhood Cancer41 topic
- JAK2 Mutation41 topic
- Myelofibrosis41 topic
- Cetuximab31 topic
- KRAS Mutations31 topic
Where does Chengqing Wu work?
Chengqing Wu's main affiliation in the publication record is Cornell University, United States.
How many publications and citations does Chengqing Wu have?
OpenAlex counts 34 works and 608 citations for Chengqing Wu, an h-index of 9, ranking #4,319,047 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Other researchers named Chengqing Wu
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Chengqing Wu. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.